



# Resmetirom and Obeticholic Acid for Non-Alcoholic Steatohepatitis (NASH)

## Questions for Deliberation and Voting: April 28, 2023 Public Meeting

*These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.*

**Patient Population for all questions:** Adults with Non-Alcoholic Steatohepatitis (NASH) with significant fibrosis (i.e., stage 2 and stage 3 fibrosis) and not cirrhosis.

### Clinical Evidence

1. Is the evidence adequate to demonstrate that the net health benefit of **resmetirom** is superior to that provided by **lifestyle management alone**?

Yes                      No

Is the evidence adequate to demonstrate that the net health benefit of **obeticholic acid** is superior to that provided by **lifestyle management alone**?

Yes                      No

### Contextual Considerations and Potential Other Benefits or Disadvantages

*Please vote on the following contextual considerations:*

**When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for NASH with fibrosis, on the basis of the following contextual considerations:**

1= Very low priority; 2 = Low priority; 3 = Average priority; 4 = High priority; 5= Very high priority

2. Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability
3. Magnitude of the lifetime impact on individual patients of the condition being treated

*Please vote on the following potential other benefits or disadvantages:*

**What are the relative effects of resmetirom versus lifestyle management alone on the following outcomes that inform judgment of the overall long-term value for money of resmetirom?**

1= Major negative effect; 2 = Minor negative effect; 3 = No difference; 4 = Minor positive effect; 5 = Major positive effect

4. Patients' ability to achieve major life goals related to education, work, or family life
5. Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life
6. Society's goal of reducing health inequities

### **Long-Term Value for Money**

7. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with **resmetirom** versus **lifestyle management alone**?\*
  - a. Low long-term value for money at current prices
  - b. Intermediate long-term value for money at current prices
  - c. High long-term value for money at current pricing
8. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with **obeticholic acid** versus **lifestyle management alone**?†
  - a) Low long-term value for money at current prices
  - b) Intermediate long-term value for money at current prices
  - c) High long-term value for money at current pricing

\*This vote will only be taken if a price becomes available for resmetirom.

†This vote will only be taken if a price becomes available for obeticholic acid for the indication of NASH.